Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 30.7% in December

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 49,723 shares, a drop of 30.7% from the November 30th total of 71,799 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 41,656 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily trading volume, of 41,656 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.0% of the shares of the stock are sold short.

Evogene Stock Down 2.9%

Shares of Evogene stock traded down $0.03 during mid-day trading on Monday, hitting $1.01. The stock had a trading volume of 25,367 shares, compared to its average volume of 586,461. The firm has a 50-day moving average of $1.15 and a two-hundred day moving average of $1.24. The firm has a market cap of $5.40 million, a P/E ratio of -2.01 and a beta of 1.37. Evogene has a 12-month low of $0.95 and a 12-month high of $2.42.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 20th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.10. The company had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.65 million. Evogene had a negative return on equity of 75.09% and a negative net margin of 52.33%.

Hedge Funds Weigh In On Evogene

A number of hedge funds have recently made changes to their positions in EVGN. Armistice Capital LLC raised its holdings in shares of Evogene by 5.9% in the 1st quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 17,743 shares during the period. Citadel Advisors LLC boosted its stake in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. Finally, Jane Street Group LLC lifted its stake in Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the last quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.50.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.